JP2023123854A5 - - Google Patents

Download PDF

Info

Publication number
JP2023123854A5
JP2023123854A5 JP2023112365A JP2023112365A JP2023123854A5 JP 2023123854 A5 JP2023123854 A5 JP 2023123854A5 JP 2023112365 A JP2023112365 A JP 2023112365A JP 2023112365 A JP2023112365 A JP 2023112365A JP 2023123854 A5 JP2023123854 A5 JP 2023123854A5
Authority
JP
Japan
Prior art keywords
chloro
dihydroquinazolin
oxo
sulfonamide
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023112365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023123854A (ja
Filing date
Publication date
Priority claimed from JP2022575381A external-priority patent/JP7312335B2/ja
Application filed filed Critical
Publication of JP2023123854A publication Critical patent/JP2023123854A/ja
Publication of JP2023123854A5 publication Critical patent/JP2023123854A5/ja
Pending legal-status Critical Current

Links

JP2023112365A 2020-06-09 2023-07-07 Braf関連疾患および障害を処置するための4-オキソ-3,4-ジヒドロキナゾリノン化合物 Pending JP2023123854A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063036522P 2020-06-09 2020-06-09
US63/036,522 2020-06-09
US202063116204P 2020-11-20 2020-11-20
US63/116,204 2020-11-20
US202163175655P 2021-04-16 2021-04-16
US63/175,655 2021-04-16
JP2022575381A JP7312335B2 (ja) 2020-06-09 2021-06-04 Braf関連疾患および障害を処置するための4-オキソ-3,4-ジヒドロキナゾリノン化合物
PCT/IB2021/054919 WO2021250521A1 (en) 2020-06-09 2021-06-04 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022575381A Division JP7312335B2 (ja) 2020-06-09 2021-06-04 Braf関連疾患および障害を処置するための4-オキソ-3,4-ジヒドロキナゾリノン化合物

Publications (2)

Publication Number Publication Date
JP2023123854A JP2023123854A (ja) 2023-09-05
JP2023123854A5 true JP2023123854A5 (https=) 2024-05-29

Family

ID=76355554

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022575381A Active JP7312335B2 (ja) 2020-06-09 2021-06-04 Braf関連疾患および障害を処置するための4-オキソ-3,4-ジヒドロキナゾリノン化合物
JP2023112365A Pending JP2023123854A (ja) 2020-06-09 2023-07-07 Braf関連疾患および障害を処置するための4-オキソ-3,4-ジヒドロキナゾリノン化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022575381A Active JP7312335B2 (ja) 2020-06-09 2021-06-04 Braf関連疾患および障害を処置するための4-オキソ-3,4-ジヒドロキナゾリノン化合物

Country Status (20)

Country Link
US (2) US12303509B2 (https=)
EP (1) EP4161907A1 (https=)
JP (2) JP7312335B2 (https=)
KR (1) KR102904179B1 (https=)
CN (1) CN116096710B (https=)
AU (1) AU2021289163B2 (https=)
CL (1) CL2022003326A1 (https=)
CO (1) CO2022017876A2 (https=)
CR (1) CR20220626A (https=)
DO (1) DOP2022000282A (https=)
EC (1) ECSP22093029A (https=)
IL (1) IL298300B1 (https=)
MX (1) MX2022015703A (https=)
PE (1) PE20231651A1 (https=)
PY (1) PY2146661A (https=)
TW (2) TW202426436A (https=)
UA (1) UA130198C2 (https=)
UY (1) UY39261A (https=)
WO (1) WO2021250521A1 (https=)
ZA (1) ZA202212876B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
AU2020403082A1 (en) * 2019-12-10 2022-05-12 F. Hoffmann-La Roche Ag New BRAF inhibitors as paradox breakers
PH12022551119A1 (en) 2019-12-10 2023-08-23 Hoffmann La Roche New methylquinazolinone derivatives
TW202426436A (zh) * 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和病症之化合物
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶-1,6(2h,7h)-二酮
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
US20250011304A1 (en) * 2021-12-08 2025-01-09 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
US20230293465A1 (en) * 2022-03-17 2023-09-21 St. Jude Children’S Research Hospital Treatment of low-grade glioma with mirdametinib
WO2023183470A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024054591A1 (en) * 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2024126660A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
WO2025014933A1 (en) * 2023-07-10 2025-01-16 Northwestern University Targeting tim-3 in mapk-driven glioma
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
WO2025176139A1 (zh) * 2024-02-20 2025-08-28 海思科医药集团股份有限公司 一种喹唑啉酮衍生物的晶型及其制备方法和应用
WO2026037755A1 (en) * 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
CA2577275A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
ES2405785T3 (es) 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
JP2009532450A (ja) 2006-04-05 2009-09-10 アストラゼネカ アクチボラグ 化合物
CN101415689A (zh) 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有抗癌活性的经取代的喹唑啉
CN101421253A (zh) 2006-04-18 2009-04-29 阿斯利康(瑞典)有限公司 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
RU2622015C2 (ru) 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
AU2017204973A1 (en) 2016-01-06 2018-07-12 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as EGFR inhibitors
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
EP3684772B1 (en) 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
RU2678455C1 (ru) 2018-06-01 2019-01-29 Сергей Викторович Леонов Кристаллическая форма n-(3-(5-(4-хлорофенил)-1н-пиразоло[3,4-в]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамида, активный компонент, фармацевтическая композиция и лекарственное средство
US11661075B2 (en) 2018-09-11 2023-05-30 NetraDyne, Inc. Inward/outward vehicle monitoring for remote reporting and in-cab warning enhancements
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物
PH12022551119A1 (en) 2019-12-10 2023-08-23 Hoffmann La Roche New methylquinazolinone derivatives
AU2020403082A1 (en) * 2019-12-10 2022-05-12 F. Hoffmann-La Roche Ag New BRAF inhibitors as paradox breakers
TW202426436A (zh) * 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和病症之化合物

Similar Documents

Publication Publication Date Title
JP2023123854A5 (https=)
JP2022520448A5 (https=)
RU2440330C2 (ru) ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
JP2022520811A5 (https=)
RU2373209C2 (ru) Пирролотриазиновые соединения как ингибиторы киназ
RU2010150786A (ru) Пирролопиридины как ингибиторы киназы
RU2486181C2 (ru) Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2020033357A5 (https=)
RU2002121645A (ru) Производные 2-аминоникотинамида и их применение в качестве ингибиторов vegf-рецептора тирозинкиназы
JP2022534979A5 (https=)
RU2015122414A (ru) Соединения n-пирролидинилмочевины, n'-пиразолилмочевины, тиомочевины, гуанидина и цианогуанидина как ингибиторы киназы trka
JP2021523221A5 (https=)
JP2021529812A5 (https=)
RU2015106605A (ru) Соединения замещенных пиразолонов и способы использования
JP2018138577A5 (https=)
JP2023536164A5 (https=)
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
RU2008137526A (ru) Ингибиторы киназы, основанные на гидантоине
JP2017525757A5 (https=)
JP2020503299A5 (https=)
JP2013503903A5 (https=)
EA200400830A1 (ru) ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ОТНОСЯЩИЕСЯ К A2b-СЕЛЕКТИВНЫМ АНТАГОНИСТАМ, ИХ СИНТЕЗ И ПРИМЕНЕНИЕ
JP2013538801A5 (https=)
RU2010145463A (ru) Производные замещенного 2-фенилпиридина